ATLANTA, Georgia (AP) -- An expensive vaccine aimed at preventing cervical cancer makes sense for young teens when it comes to cost-effectiveness, but not for women in their 20s, contends a new report. Health officials recommended the cervical...

More-articles

A new study suggests that giving Merck & Co.'s cervical-cancer vaccine Gardasil to women through their mid-20s may not be worth the price, despite U.S. recommendations that this age group receive the costly shot. The study, published online...
A new economic analysis shows that the HPV vaccine, which protects against the viruses that cause most cervical cancers and genital...
See all

Blog-posts

Well, now we have this. Two vaccines against cervical cancer are being widely used without sufficient evidence about whether they are worth their high cost or even whether they will effectively stop women from getting the disease, two articles in...